Azilsartan is a new drug successfully tried on adults and now being studied on pediatric group. Here is what the study on adults has to say.

Team@CMHF

Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug Administration (FDA) for hypertension management.
The purpose of this study was to review the pharmacology, pharmacokinetics, efficacy, safety profile, and role of azilsartan for hypertension management.

METHODS: Peer-reviewed clinical trials, review articles, and relevant treatment guidelines were identified from MEDLINE and Current Contents (both 1966 to August 31, 2011) using the search terms azilsartan, TAK-491, TAK-536, pharmacology, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and cost-effectiveness. The FDA Web site and manufacturer prescribing information were also reviewed to identify other relevant information.

RESULTS: Compared with olmesartan 40 mg daily, azilsartan 80 mg reduced mean systolic blood pressure (SBP) by an additional 2.1 mm Hg , whereas azilsartan 40 mg was noninferior to olmesartan 40 mg. Azilsartan 40 mg or 80 mg added to chlorthalidone 25 mg daily significantly reduced SBP to a greater extent than did chlorthalidone alone, but there was no difference between azilsartan 40 mg and 80 mg (4:  When coadministered with amlodipine 5 mg daily, both azilsartan 40 mg and 80 mg + amlodipine decreased SBP significantly more than amlodipine alone ; with azilsartan 80 mg: [P<0.05]).Compared with ramipril 10 mg daily, both azilsartan 40 mg and 80 mg resulted in significantly (P<0.001) greater reductions in mean SBP . The most common adverse events reported were dizziness (4%), dyslipidemia (3.3%), and diarrhea (2%).

CONCLUSIONS: At the recommended dose of 80 mg once daily, azilsartan is reported to be an efficacious BP-lowering agent. With once-daily dosing and a favorable side-effect profile, azilsartan is an attractive option for the treatment of hypertension. There is a lack of data supporting the use of azilsartan for improvement in cardiovascular outcomes; therefore, azilsartan is not approved for indications other than the treatment of hypertension.

Ref: http://www.docguide.com/azilsartan-medoxomil-new-angiotensin-receptor-blocker?hash=80445d1a&eid=23173&alrhash=2efbb8-880279c42369cc2f8adcb48a6daaf3d2